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Recognition of Major DNA Adducts of Enantiomeric
Cisplatin Analogs by HMG Box Proteins
and Nucleotide Excision Repair of These Adducts
hypothesis that O6-NH [3–6] and/or phosphate-NH intra-
molecular hydrogen bonds within the 1,2-intrastrand CL
affect DNA conformation and hence activity of the plati-
num compound [4–12].
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Because DNA (and several other cellular substrates)
is a chiral molecule, it may interact in a different wayWe examined HMG domain protein recognition of ma-
with the platinum complexes containing enantiomericjor 1,2-GG intrastrand DNA crosslinks, formed by two
amine ligands such as ((1R,2R)-diaminocyclohexane)-bifunctional enantiomeric analogs of antitumor cis-
platinum(II) and ((1S,2S)-diaminocyclohexane)platinum(II)diamminedichloroplatinum(II) (cisplatin), and removal
[Pt(R,R-DACH) and Pt(S,S-DACH), respectively; DACH of these crosslinks during in vitro nucleotide excision
1,2-diaminocyclohexane] [13–15]. Although Pt(R,R-repair (NER) reactions. Electrophoretic mobility shift
DACH) and Pt(S,S-DACH) produce the same kind ofassays show that domains A and B of HMGB1 pro-
intra- and interstrand DNA CLs (which are similar totein bind to (2R,3R)-diaminobutanedichloroplatinum(II)-
those formed by cisplatin) [16], the biological activity ofgenerated crosslinks with a higher affinity than to
the two enantiomers is different [17–26]. Generally, thethose generated by (2S,3S)-diaminobutanedichloro-
differences in biological activity of enantiomeric formsplatinum(II). The crosslinks of both enantiomers are
of platinum(II) compounds with chiral amine ligands areremoved by NER with a similar efficiency; however,
not so pronounced unless the rotational freedom of theHMG1B protein significantly inhibits removal of the
asymmetric center is reduced by placing, for instance,(2R,3R)-diaminobutaneplatinum(II) adduct, but not that
the chiral center(s) on the carbon chain linking two nitro-of the (2S,3S) enantiomer. Thus, HMG domain proteins
gen atoms of a chelate diamine [17–20, 22, 25, 26]. Thus,discriminate among different conformations of the 1,2-
for instance, it has been found [17–20, 22, 25, 26] thatGG intrastrand crosslinks of the two enantiomeric ana-
Pt(R,R-DACH) exhibits higher antitumor activity thanlogs of cisplatin, which results in different NER of these
Pt(S,S-DACH).crosslinks. This observation may provide insight into
Chiral carbon atoms in the chain bridging the twothe mechanisms underlying antitumor activity of cis-
nitrogens influence both the puckering of the chelateplatin and its analogs.
ring (particularly in the case of five-membered chelate
rings) and the stereochemistry on the coordinated nitro-
Introduction gens with one “quasi axial“ and one ”quasi equatorial“
hydrogen. There is a relationship between antitumor
The mechanism of antitumor activity of cis-diamminedi- efficiency of the platinum compound and the conforma-
chloroplatinum(II) (cisplatin) is of continuing interest tion of the five-membered chelate ring of the diamine
because understanding it may help in designing new in the carrier ligand of the platinum drug. Usually, the
platinum drugs with better or alternative therapeutic compounds with a-gauche conformation of the chelate
properties. One concept of designing new platinum ring exhibit higher antitumor activity than those having
drugs is based on the observation that carrier amine a -gauche conformation [19]. In contrast, compounds
ligands of cisplatin can modulate its anticancer proper- with a -gauche conformation of the chelate ring of the
ties. For instance, activity is usually lost or diminished diamine exhibit higher mutagenic activity which, in some
if the primary or secondary amines on platinum are re- cases, can be even ten times greater than that of the
placed by tertiary amines [1]. Cisplatin reacts with a other enantiomer [22]. As a result of the markedly dif-
number of cellular components, but it is generally ac- ferent behavior of the two enantiomeric forms, only
cepted that the biologically relevant target is DNA [2]. ((1R,2R)-diaminocyclohexane)oxalatoplatinum(II) (oxa-
Cisplatin preferentially reacts with N7 atoms of neigh- liplatin) (having a -gauche conformation of the chelate
boring purines in DNA (either two guanines or adenine ring) and not the S,S enantiomer has been approved in
and guanine), giving rise to 1,2-GG intrastrand crosslinks Europe, Latin America, and Asia for clinical use [27].
(CLs). The dependence of the activity of cisplatin ana- Hence, studies have mainly focused on DNA modifica-
logs on the character of carrier ligands has led to the tions by the complex having the R,R-DACH ligand. The
recently reported [28, 29] crystal structure of 1,2-GG
intrastrand CL formed by oxaliplatin in a DNA dodeca-3 Correspondence: brabec@ibp.cz
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the carbon atoms of the carrier ligand in cisplatin ana-
logs can affect processing its major adducts in cells,
we investigated in the present work how HMGB1 box
proteins and the NER differentiate between major DNA
adducts of cisplatin analogs having enantiomeric non-
leaving ligands during in vitro reactions. We have chosen
for these studies Pt(R,R-DAB) and Pt(S,S-DAB) com-
pounds as the representatives of cisplatin analogs with
enantiomeric amine ligands because the effect of chiral-
Figure 1. Structures of the Platinum Compounds Tested in the Pres- ity at the carbon atoms on the biological activity was
ent Study most pronounced in the case of this class of cisplatin
analogs [22]. Thus, the results of the present work may
also serve to clarify the role of enantiomorphism of car-
nucleotide duplex has shown that the overall geometry rier ammine ligands in oxaliplatin, the second-genera-
is similar to that of cisplatin. A novel feature of this tion platinum anticancer drug already used in the clinic.
structure is the presence of a hydrogen bond between
the pseudoequatorial NH hydrogen atom of the R,R-
DACH ligand and the O6 atom of the 3-G of the CL. Results
This finding has confirmed the importance of chirality
in mediating the interaction between cisplatin analogs Recognition by the Domains A and B of HMGB1
To determine the effect of chirality at the carbon atomscontaining enantiomeric amine ligands and double-heli-
cal DNA. In addition, a very recent report [30] has dem- of the carrier ligand in cisplatin analogs on the recogni-
tion of platinated DNA by HMGB1 box proteins, we in-onstrated that HMGB1 and TATA binding proteins rec-
ognize 1,2-GG intrastrand CL of Pt(R,R-DACH). vestigated the interactions of the rat HMGB1 domain A
(HMGB1a) and HMGB1 domain B (HMGB1b) with 1,2-Several attempts have been made to find relationships
between the configuration of the carrier ligands of the GG intrastrand CLs of Pt(R,R-DAB) or Pt(S,S-DAB). In
these experiments, the 20 base pair (bp) duplex TGGT/platinum complexes and structural modifications in-
duced in DNA by these compounds and/or cellular pro- AGGA(1) (Table 1) was modified so that it contained a
single, site-specific 1,2-GG intrastrand CL of Pt(R,R-cessing of the resulting DNA damage. We have shown
in our recent work [31] that 1,2-d(GpG) intrastrand CL DAB), Pt(S,S-DAB), or, for comparative purposes, also
that of cisplatin. The binding of HMGB1a and HMGB1bof ((2R,3R)-diaminobutane)platinum(II) or ((2S,3S)-diami-
nobutane)platinum(II) [Pt(R,R-DAB) or Pt(S,S-DAB), re- to these DNA probes was detected by retardation of the
migration of the radiolabeled 20 bp probes through thespectively; DAB  2,3-diaminobutane] (Figure 1) not
only destabilize DNA differently but also bend and un- gel [34, 39, 40] (Figure 2).
HMGB1a and HMGB1b exhibited negligible binding towind DNA to a different extent. DNA containing platinum
adducts that induce stable directional bending and un- the nonmodified 20 bp duplex. As indicated by the pres-
ence of a shifted band whose intensity increases withwinding attracts various damaged-DNA binding pro-
teins, such as those containing the high-mobility group increasing protein concentration (shown for HMGB1a in
Figure 2A), both HMGB1a and HMGB1b recognize the(HMG) domain [32–35]. The affinity of these proteins to
1,2-GG intrastrand CLs of cisplatin depends on several duplex containing the 1,2-GG intrastrand CL of either
Pt(R,R-DAB) or Pt(S,S-DAB). Because only a single-factors and the efficiency of the adducts to thermody-
namically destabilize DNA is among the most important. shifted band forms after incubation of TGGT/AGGA(1)
duplex containing the CL with either HMGB1a orThe binding of these proteins has been postulated to
mediate the antitumor properties of the platinum drugs HMGB1b, detailed titration studies were possible. The
results of the titration of this duplex containing the 1,2-[34, 35]. In addition, several reports [36–38] have demon-
strated that intrastrand CLs of cisplatin and its direct GG intrastrand CL of either Pt(R,R-DAB) or Pt(S,S-DAB)
with HMGB1a or HMGB1b are shown in Figures 2B andanalogs are removed from DNA during nucleotide exci-
sion repair (NER) reactions and that NER is also an 2C, respectively. Evaluations of these titration data af-
forded the KD(app) values reported in Table 2. These titra-important mechanism contributing to cisplatin resis-
tance. tion data indicate that HMGB1a binds the probe con-
taining the CL of Pt(R,R-DAB) with a relatively highTherefore, in order to shed light on how chirality at
Table 1. Oligodeoxyribonucleotide Sequences and Abbreviations
Abbreviation Sequence
TGGTa 5-CCTCTCCTTGGTCTTCTTCT-3
ACCA(1) 5-AGAAGAAGACCAAGGAGAGG-3
ACCA(2) 5-GCTCAGAAGAAGACCAAGGAGAGGTCAG-3
64-mer(1) 5-GGGACCTGAACACGTACGGAATTCGATATCCTCGAGCCAGATCTGCGCCAGCTGGCCACCCTGA-3
64-mer(2) 5-GAGCGCCAAGCTTGGGCTGCAGCAGGTCGACTCTAGAGGATCCCGGGCGAGCTCGAATTCGCCC-3
61-mer 5-GGGGCGAATTCGAGCTCGCCCGGGATCCTCTAGAGTCGACCTGCTGCAGCCCAAGCTTGGC-3
59-mer 5-GGTGGCCAGCTGGCGCAGATCTGGCTCGAGGATATCGAATTCCGTACGTGTTCAGGTCC-3
a Bold face indicates the sites of platination.
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Table 2. KD(app) Values Determined for HMGB1 Box Protein
Interactions with 20 bp Oligonucleotide Duplexes TGGT/
ACCA(1) Containing Single 1,2-GG Intrastrand Crosslink of
Pt(R,R-DAB), Pt(S,S-DAB), or Cisplatin
Duplex HMGB1a HMGB1b
20 bp/R,Ra 11  2 320  34
7  1d
20 bp/S,Sb 113  19d 510  60
20 bp/cisplatinc 26  3
14  2d
KD(app) values are in nM and were measured by direct titration unless
otherwise specified.
a The duplex containing the adduct of Pt(R,R-DAB).
b The duplex containing the adduct of Pt(S,S-DAB).
c The duplex containing the adduct of cisplatin.
d Measured from competition experiments.
duplex TGGT/ACCA(1) containing the CL of either en-
antiomer or cisplatin competes with the binding of
HMGB1a to labeled duplex TGGT/ACCA(1) containing
the 1,2-GG intrastrand CL of cisplatin (shown in Figure
3A for the unlabeled probe containing the CL of Pt(R,R-
DAB)). A plot quantitating these competition data is pre-
sented in Figure 3B. The apparent dissociation con-
stants for the competitors, such as duplexes containing
the 1,2-GG intrastrand CL of Pt(R,R-DAB), Pt(S,S-DAB),
or cisplatin were determined as described [41] and are
given in Table 2. These data confirmed that HMGB1a
Figure 2. Gel Mobility Shift Assay Analysis of the Titration of the 20
bp Duplex TGGT/ACCA(1) Containing the Single 1,2-GG Intrastrand
CL of Pt(R,R-DAB) or Pt(S,S-DAB) with HMGB1a and HMGB1b
(A) Autoradiogram of gel mobility shift assay of the titration with
HMGB1a (0.5 nM–1.4 M). The concentration of the 20 bp duplex
was 10 nM.
(B) Plots of the fraction of bound DNA () versus HMGB1a concentra-
tion with superimposed fits to the equation   P/P  KD(app) (P is the
total protein concentration, and KD(app) is the apparent dissociation
constant) [41, 71]. DNA probes were the 20 bp duplex TGGT/ACCA(1)
(10 nM) containing the single 1,2-GG intrastrand CL of Pt(R,R-DAB)
(squares), Pt(S,S-DAB) (circles) or cisplatin (triangles).
(C) Plots of the fraction of bound DNA () versus HMGB1b concentra-
tion with superimposed fits to the equation given in the legend to
Figure 3. Analysis of the Self-Competition of the Complex ofFigure 2B. Other details were the same as in Figure 2B.
HMGB1a with the 20 bp Duplex TGGT/ACCA Containing the 1,2-
GG Intrastrand CL of Cisplatin with Unlabeled Competitor TGGT/
ACCA(1) Containing the 1,2-GG Intrastrand CL of Pt(R,R-DAB)
affinity, which was even higher than that of HMGB1a to
(A) Gel mobility shift assay. The 20 bp duplex TGGT/ACCA was atthe same probe containing the CL of cisplatin. On the
a concentration of 10 nM.
other hand, the binding of HMGB1a to the probe con- (B) Plot of the fraction of bound DNA  versus competitor concentra-
taining the CL of Pt(S,S-DAB) was considerably re- tion for unlabeled TGGT/ACCA(1) competitors containing the 1,2-
GG intrastrand CL of Pt(R,R-DAB) (squares), Pt(S,S-DAB) (circles),duced; for instance, the fraction of bound oligonucleo-
or cisplatin (triangles) with the duplex containing the 1,2-GG intra-tide probe was only 0.3 at a protein concentration as
strand CL of cisplatin. Fits of the data to the equation   1/2Tt{Kt high as 1 M. Because a relatively high amount of the
KrelCt  Pt  Tt 	 [(KtKrelCtPtTt)2 	 4PtTt ]1/2} (Krel is the ratio ofHMGB1a protein would be needed to complete the titra-
Kt [the apparent dissociation constant of the labeled probe] to thetion experiment with the probe containing the CL of apparent dissociation constant of the competitor, and Pt, Tt, and Ct
Pt(S,S-DAB), this binding was also investigated via a are the concentrations of protein, radiolabeled probe, and competi-
tor probe, respectively [41, 72]) are superimposed.competition assay (Figure 3). Addition of the unlabeled
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Figure 4. Excision of 1,2-GG Intrastrand
Crosslinks of Pt(R,R-DAB), Pt(S,S-DAB), or
Cisplatin by Rodent Excinuclease
(A) Substrates (148 bp) containing the central
and unique intrastrand CL of Pt(R,R-DAB)
(lane RR), Pt(S,S-DAB) (lane SS), or cisplatin
(lane cisPt) were incubated with CHO CFE
and resolved in 10% denaturing polyacryl-
amide gel. Excision products released during
the reaction are primarily 23–28 nucleotides
in length and are not observed in the absence
of CFE (not shown). In this experiment, the
percentages of excision by CHO CFE were
around 7%.
(B) Mapping of incision sites. Time course
analysis with T4 DNA polymerase and 20-mer
duplexes containing the 1,2-GG intrastrand
CL of Pt(R,R-DAB) or Pt(S,S-DAB) formed at
the central sequence TGGT were used to
identify sites of inhibition of T4 DNA polymer-
ase exonuclease activity. At all time points,
this exonuclease activity was primarily
blocked at the second or first nucleotide 3
to the CL of Pt(R,R-DAB) or Pt(S,S-DAB), re-
spectively, resulting in the migration of plati-
nated 20-mers as platinated 12- or 11-mers.
(C) Limited (10 min) T4 DNA polymerase di-
gestion was used to identify the 3 incision
site of gel-purified oligomers released during
the excision repair reaction (Figure 4A, lanes
RR and SS). The excised 28-mers containing
the CL of Pt(R,R-DAB) (lane 1) or Pt(S,S-DAB) (lane 2) migrated as a 19-mer (lane 4) or 18-mer (lane 5), respectively, after treatment with T4
DNA polymerase. Lane 3 contains the mixture of single-stranded oligodeoxyribonucleotides 18–28 nucleotides long as the markers. Thus, in
the case of both CLs, one incision occurs at the 11th phosphodiester bond 3 to the CL, and the second incision occurs at the 17th bond on
the 5 side to generate a 28-mer excision product. For other details, see the text.
binds to the 1,2 GG intrastrand CL of Pt(R,R-DAB) with The NER assay detects radiolabeled fragments resulting
from dual incisions both 5 and 3 to the lesion. Theapproximately two times or 16 times higher affinity than
was that to the CL of cisplatin or Pt(S,S-DAB), respec- length of the major excision products, generated by NER
of the 1,2-GG intrastrand CLs of Pt(R,R-DAB) or Pt(S,S-tively.
The titration of the 20-bp duplex containing the 1,2- DAB) (Figure 4A, lanes RR and SS) was determined in
the following way. The excised fragments were cut offGG intrastrand CL of Pt(R,R-DAB) or Pt(S,S-DAB) with
HMGB1b has revealed (Figure 2B) that this protein also from the gel, isolated, and purified, and their length was
determined by a comparison of their electrophoreticbinds to the intrastrand CL of these platinum com-
pounds, although with considerably less affinity (30 mobility in the gel with the mobility of the unplatinated
marker oligodeoxyribonucleotides. This determinationtimes less) than that with which HMGB1a binds to
the probes crosslinked by Pt(R,R-DAB) or cisplatin. is, however, complicated by the fact that the mobility
of the excised fragments is affected by the 2 charge ofHMGB1b binds to the probes that are intrastrand cross-
linked by both enantiomers with approximately the same the platinum complex moiety. The decreased mobility
of the excised platinated fragments was, therefore, re-affinity, although the affinity to the CL of Pt(S,S-DAB)
was slightly lower. versed by NaCN treatment (0.2 M, pH 10–11, 45
C over-
night), which removes platinum from DNA. The following
analysis revealed that the major excision fragment con-Nucleotide Excision Repair
NER is a pathway used by human cells for the removal of tained 28 nucleotides and that the other primary excision
fragments were 23–27 nucleotides in length (vide supra),damaged nucleotides from DNA [42–44]. In mammalian
cells, this repair pathway is an important mechanism for although 22–31 nucleotide-long fragments were also ob-
served (Figure 4A, lanes 2–4). This range of productthe removal of bulky, helix-distorting DNA adducts, such
as those generated by various chemotherapeutics, in- sizes reflects variability at both the 3 and 5 incision
sites [37, 49]; smaller excision products are due to deg-cluding cisplatin [45]. Efficient repair of 1,2-GG and 1,3-
GTG intrastrand CLs of cisplatin by various NER sys- radation of the primary excision products by exo-
nucleases present in the extracts [37].tems, including human and rodent excinucleases, has
been reported [36–38, 46–48]. The result presented in T4 DNA polymerase 3→5 exonuclease activity was
used to map the primary sites of incision. If a DNA adductFigure 4A, lane 2 confirms these reports. Importantly,
1,2-GG intrastrand CL of Pt(R,R-DAB) or Pt(S,S-DAB) terminates the exonuclease activity so that it is a block
to this activity, limited digestion with the exonucleasewas also repaired with a similar efficiency by both human
and rodent excinucleases (shown for the CLs repaired demonstrates that the damaged nucleotide(s) is in the
excised oligomer. In addition, the limited digestion canby rodent excinuclease in Figure 4A, lanes RR and SS).
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also be used to map the 3 incision site. Incubation of
the 20-mer TGGT containing the single 1,2-GG intra-
strand CL of either DAB enantiomer (used to prepare
the 148 bp duplex as the substrate for the nucleotide
excision assay) with T4 DNA polymerase in the absence
of deoxyribonucleotide triphosphates (i.e., exploiting
3→5 exonuclease activity of this polymerase) was used
to determine the nucleotide at which the exonuclease
activity is inhibited. Interestingly, after incubation of the
20-mer oligonucleotides containing the CL of Pt(R,R-
DAB) or Pt(S,S-DAB) (10 min) with T4 DNA polymerase
under these conditions, the resulting products migrated
as a species 8 or 9 nucleotides less than the starting
material (Figure 4B), indicating that the exonuclease ac-
tivity was blocked at the first nucleotide 3 to the intra-
strand CL or directly at the 3 guanine of the CL, respec-
tively.
When the 28-mer excision product, generated by re-
pair of the 1,2-GG intrastrand CL of Pt(R,R-DAB) or
Pt(S,S-DAB), was treated in the same manner, it was
shortened by 9 or 10 nucleotides, respectively (Figure
4C). Because the data with the 20-mer show that T4
DNA polymerase 3→5 exonuclease activity stops one
nucleotide 3 to the CL or directly at the 3 guanine of
the CL, they imply that the 3 incision site is 10 nucleo-
tides (or at the 11th phosphodiester bond) 3 to the CL
of both DAB enantiomers. This in turn places the other
incision site at the 17th phosphodiester bond 5 to the
CL of both enantiomers.
Figure 5. Effect of HMGB1 on NER of the 1,2-GG Intrastrand CL of
Inhibition of Nucleotide Excision Repair Pt(R,R-DAB) or Pt(S,S-DAB) by Rodent Excinuclease
by Full-Length HMGB1 Protein (A) Denaturing 10% polyacrylamide gel showing inhibition of exci-
It has been shown [36, 50] that various HMGB1 proteins sion of the CLs of Pt(R,R-DAB) (lanes 1–4) or Pt(S,S-DAB) (lanes
specifically inhibit NER of the 1,2-GG or AG intrastrand 5–8). The 148 bp substrates containing the single and central CL
were incubated with the indicated concentrations of HMGB1 for 1CL of cisplatin. In addition, we have shown in the present
hr on ice under NER assay conditions prior to the addition of thework that HMGB1a, which is the dominating domain
rodent CFE and further incubation for 40 min.in full-length HMGB1 that binds to the site of the 1,2
(B) Plot of four NER experiments such as those shown in panel A.
intrastrand CL of cisplatin [40, 51], binds with a markedly The 148 bp substrates 1,2-GG crosslinked by Pt(R,R-DAB) (squares)
higher affinity to the CL of Pt(R,R-DAB) than to that or Pt(S,S-DAB) (circles). Data points are averages of three experi-
of its S,S enantiomer. When the excision assay was ments.
conducted by the addition of rodent cell-free extract
(CFE) to the reaction mixtures containing HMGB1 and
crosslinked DNA, excision of the 1,2-GG intrastrand CL Discussion
of Pt(R,R-DAB) was monotonically inhibited with in-
creasing protein concentration, whereas excision of the As shown for the 1,2-GG intrastrand CL of cisplatin [31],
HMGB1a binds to DNA around the site of this adduct1,2-GG intrastrand CL of Pt(S,S-DAB) was not affected
by HMGB1 addition at the concentrations up to19 M in the minor groove, whereas the amine ligands coordi-
nated to platinum reside in the major groove. It is there-and was then inhibited at higher concentrations (Figure
5). Hence, consistent with the higher affinity of the fore unlikely that the different affinity of HMGB1a to the
1,2-GG intrastrand CLs of Pt(R,R-DAB) and Pt(S,S-DAB)HMGB1a to the 1,2-GG intrastrand CL of Pt(R,R-DAB)
(Figure 2; Table 2), excision of this CL was inhibited by is due to different direct interactions of the enantiomeric
nonleaving ligands with the protein. Some structural fea-HMGB1 markedly more than that of the CL of its S,S
enantiomer (Figure 5). In comparison with that of the tures of DNA containing the 1,2-GG intrastrand CL of
Pt(R,R-DAB) and Pt(S,S-DAB) have been determinedS,S enantiomer, inhibition of NER of the 1,2-GG intra-
strand CL of the R,R enantiomer by HMGB1 was markedly and have revealed considerable differences [31]. The
most striking difference is DNA bending induced byhigher in HeLa CFE as well (our unpublished data). The
fact that NER of the 1,2-GG intrastrand CL of Pt(R,R- these adducts. Whereas the 1,2-GG intrastrand CL of
Pt(R,R-DAB) bends DNA only slightly more than cisplatinDAB) is blocked by HMGB1 at concentrations of protein
that do not inhibit NER of the 1,2-GG intrastrand CL of (the bending angles determined by a phasing assay were
35
 or 32–34
 for the CLs of Pt(R,R-DAB) or cisplatin,Pt(S,S-DAB) is consistent with the view that this effect
is not a consequence of nonspecific inhibition of the respectively), the CL of the S,S enantiomer bends DNA
considerably less (24
) [31]. Thus, this result is consistentrepair factors by this protein [36].
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with the view that S,S-DAB ligand could restrict the stricted DNA bending, or some other features result in
the reduced affinity of HMGB1a for this adduct.bending angle of the 1,2-GG intrastrand CL. In addition,
when HMGB1a binds to the 1,2-GG intrastrand CL of As mentioned above, it is also possible that the differ-
ent affinity of the HMGB1a for the 1,2-GG intrastrandcisplatin, the protein induces further bending of the DNA
[34, 35]. Hence, it is also possible that the bulky DAB CLs of Pt(R,R-DAB) and Pt(S,S-DAB) is also associated
with the observation that the CL of Pt(S,S-DAB) inducesgroup in the 1,2-GG intrastrand CL of Pt(S,S-DAB) re-
stricts the additional DNA bending, required for a greater distortion on the 5 side of the adduct than its
R,R enantiomer [31]. The distortion on the 5 side mayHMGB1a binding, markedly more than in the CL of
Pt(R,R-DAB) or cisplatin. occur because of a new chiral interaction of the S,S-
DAB ligand. Thus, it seems reasonable to suggest thatRecently published results [28, 29] indicate several
very distinct properties of the 1,2-GG intrastrand CLs the more pronounced distortion on the 5 side of the CL
reduces affinity of the HMGB1a to the 1,2-GG intrastrandformed by cisplatin and Pt(R,R-DACH) [this latter com-
pound is closely related to Pt(R,R-DAB) examined in the CLs of cisplatin analogs. On the other hand, the CL of
Pt(R,R-DAB) induces a greater distortion on the 3 sidepresent work]. Although the hydrogen bond between
5 phosphate and cisplatin ammonia oriented toward 5 of the adduct [31]. Interestingly, HMGB1a makes con-
tacts with DNA containing the 1,2-GG intrastrand CL ofguanine in the platinated site is readily formed, this type
of hydrogen bond does not occur if cisplatin in this CL cisplatin asymmetrically and mainly on the 3 side of the
CL [40]. Thus, the latter result is consistent with theis replaced by Pt(R,R-DACH). On the other hand, a new
chiral interaction is observed in the CL formed by Pt(R,R- somewhat surprising hypothesis that the distortion on
the 3 side of the CL formed by the R,R enantiomer doesDACH). This new interaction involves the hydrogen
bonding between the pseudo-equatorial NH of the R,R- not markedly affect the binding of HMGB1a protein to
the intrastrand CL of Pt-DAB compounds.DACH ligand and the O6 atom of the 3 guanine of the
platinated site. It is reasonable to expect that the hydro- Several reports [36–38] have demonstrated that NER
is a major mechanism contributing to cisplatin resis-gen bonding in the CLs formed by Pt(R,R-DAB) and
Pt(R,R-DACH) is similar [52, 53]. In addition, the results tance and that the binding of HMG domain proteins to
1,2-GG intrastrand CLs has been postulated to mediateof the present work (Figures 2A and 2B) demonstrate
that the affinity of HMGB1a to the 1,2-GG intrastrand antitumor properties of the platinum drugs [34, 35]. The
details of how the binding of HMG domain proteins toCLs of cisplatin and Pt(R,R-DAB) is also similar. There-
fore, hydrogen bonds between 5 cisplatin ammonia and cisplatin-modified DNA sensitizes tumor cells to cis-
platin are still not completely resolved, but possibilities5 phosphate in the platinated site or between the
pseudo-equatorial NH of the R,R-DAB ligand and the such as the shielding of platinum-DNA adducts from
NER or the titration of these proteins away from theirO6 atom of the 3 guanine of the platinated site may not
substantially affect the affinity of HMGB1a for the 1,2- transcriptional regulatory function have been suggested
[35, 56–58] as clues for how these proteins are involvedGG intrastrand CL of cisplatin or its analogs. In contrast,
it has been proposed for the CL of Pt(S,S-DAB) [52, in the antitumor activity. Our results (Figure 4A) demon-
strate that the 1,2-GG intrastrand CLs of Pt(R,R-DAB)53] that a hydrogen bond forms between the pseudo-
equatorial NH of the S,S-DAB ligand and the O6 atom of or Pt(S,S-DAB) are repaired by the NER system in vitro
with a similar efficiency. On the other hand, HMGB1the 5 guanine of the platinated site. The latter hydrogen
bond and resulting conformational distortion in DNA are protein interferes with repair of the 1,2-GG intrastrand
CL of Pt(R,R-DAB) considerably more than with that ofnot observed if the 1,2-GG intrastrand CLs of cisplatin
or R,R enantiomer is formed. This is consistent with the CL of Pt(S,S-DAB) (Figure 5). Hence, it is possible
to suggest that the stereochemistry of the carrier aminethe view that the hydrogen bond between the pseudo-
equatorial NH of the S,S-carrier ligand and the O6 atom ligands of cisplatin analogs significantly, although indi-
rectly, influences repair of their major 1,2-intrastrandof the 5 guanine of the platinated site, and perhaps
also the more extensive distortion on the 5 side of the CLs and, in this way, also the toxicity of the platinum
compounds toward cancer cell lines.CL formed by the S,S enantiomer, are the factors that
reduce the affinity of this CL to HMGB1a. It has been suggested that during replication, transle-
sion synthesis past platinum adducts catalyzed by DNAIt has been shown recently [54, 55] that the reduced
binding affinity of HMGB1a to the 1,2-GG intrastrand CL polymerases may be error prone and result in mutations.
No data that would allow comparison of translesion syn-of platinum compounds correlates with an enhanced
CL-induced energetic destabilization of the host duplex. thesis past the 1,2-GG intrastrand CL of Pt(R,R-DAB)
and Pt(S,S-DAB) are available. On the other hand, it hasIn our recent work [31], we have also analyzed by differ-
ential scanning calorimetry the 20-bp duplexes con- been shown [59, 60] that translesion synthesis past the
1,2-GG intrastrand CL of cisplatin or oxaliplatin is mark-taining the single 1,2-GG intrastrand CL of Pt(R,R-DAB)
or Pt(S,S-DAB). The CL of Pt(S,S-DAB) resulted in a edly or entirely inhibited if this CL is bound to HMGB1
protein. Hence, it is reasonable to expect that HMGB1higher destabilization of the 20 bp host duplex than the
CL of its R,R enantiomer, and consistently, the affinity proteins can modulate the efficiency of DNA polymer-
ases to bypass the 1,2-GG intrastrand CL also formedof HMGB1a to the CL of Pt(S,S-DAB) is reduced (Figures
2 and 3). by Pt-DAB compounds and can consequently affect
their mutagenicity. Thus, considerably lower mutagenicFurther molecular biophysical studies are required to
determine whether the hydrogen bond between the NH effects of Pt(R,R-DAB) in comparison with Pt(S,S-DAB)
[59, 60] could be due to markedly tighter binding of HMGof the S,S-DAB ligand and the O6 atom of the 5 guanine
of the 1,2-GG intrastrand CL of Pt(S,S-DAB), the re- domain proteins to the major 1,2-GG intrastrand CL of
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Pt(R,R-DAB) than to the CL of Pt(S,S-DAB); this tighter proteins and, consequently, for the different nucleo-
tide excision repair of these lesions. Thus, the resultsbinding would inhibit translesion synthesis past the CL
more efficiently and consequently would reduce its mu- suggest that because of the enantiomorphism of car-
rier amine ligands of cisplatin analogs, not only dotagenic effects.
This work reveals that enantiomorphism of amine li- their DNA crosslinks exhibit different conformational
features, but also these adducts are processed differ-gands affects the specific recognition by HMG box pro-
teins and NER of major DNA intrastrand CL of antitumor ently by cellular components as a consequence of
these conformational differences. As such, the resultsanalogs of cisplatin. Electrophoretic mobility shift assays
show that both the A domain of HMGB1 or full-length expand our knowledge of how stereochemistry of the
carrier amine moiety in antitumor platinum(II) com-HMGB1 discriminate between the 1,2-GG intrastrand
CLs of the two enantiomers Pt(R,R-DAB) and Pt(S,S- pounds influences some crucial processes underlying
their toxicity toward cancer cells and provide a rationalDAB). The results of the present work suggest that this
discrimination is responsible at least partly for different basis for the design of new platinum antitumor drugs
and chemotherapeutic strategies.processing of these CLs by cellular components, such
as recognition by DNA binding proteins and repair, i.e.,
Experimental Proceduresthe processes that play a crucial role in the mechanisms
underlying antitumor and mutagenic activity of platinum
Starting Materials
compounds. The effects of enantiomeric amine ligands Pt(R,R-DAB) and Pt(S,S-DAB) were prepared and characterized as
have been investigated in the present work for the 1,2- described [22]. Cisplatin was synthesized and characterized in La-
chema (Brno, Czech Republic). The stock solutions of the platinumGG intrastrand CL flanked by two thymine residues. The
complexes (0.5 mM in 10 mM NaClO4) were prepared in the darkpossibility remains that the sequence context may also
at 25
C. The synthetic oligodeoxyribonucleotides (Table 1) wereplay a role in discrimination between the intrastrand CLs
purchased from IDT (Coralville, IA) and purified as described pre-of both enantiomers of Pt-DAB compounds by DNA
viously [61, 62]; in the present work their molar concentrations are
binding proteins or by components of the repair sys- related to the whole duplexes. Acrylamide, bis(acrylamide), and
tems. Work is in progress to examine the importance NaCN were from Merck Kga (Darmstadt, Germany). T4 DNA ligase
and T4 polynucleotide kinase were purchased from New Englandof sequence context on both the conformation of DNA
Biolabs (Beverly, MA). [-32P]ATP was from Amersham (Arlingtoncontaining major 1,2-GG intrastrand CL of cisplatin ana-
heights, IL).logs with enantiomeric amine ligands and the recogni-
tion and repair of this DNA.
Preparation of Oligonucleotide Probes Containing Single,
Site-Specific 1,2-GG Intrastrand CLs
The 20 bp oligonucleotide duplex TGGT/ACCA(1) (for its nucleotide
Significance sequence, see Table 1) uniquely and site-specifically intrastrand
crosslinked by Pt(R,R-DAB), Pt(S,S-DAB), or cisplatin were prepared
and characterized as described previously [32, 61, 63, 64]. The 20-Cisplatin is one of the most effective antitumor drugs.
mer oligonucleotides containing a single, site-specific 1,2-GG in-Its clinical efficacy is, however, limited. Recently, sev-
trastrand CL of Pt(R,R-DAB), Pt(S,S-DAB), or cisplatin at the centraleral new platinum compounds that demonstrate
TGGT sequence were used for preparation of linear 148 bp duplexes
promising antitumor activities, including activity in cis- with a centrally located 1,2-GG intrastrand CL at nucleotides 75 and
platin-resistant tumors, were synthesized. One group 76. Uniquely modified 20-mers were end-labeled to introduce a
radiolabel at the tenth phosphodiester bond 5 to the CL, annealedof these compounds involves analogs of “classical”
with a set of five complementary and partially overlapping oligonu-cisplatin containing enantiomeric amine ligands; of
cleotides [ACCA(2), 64-mer(1), 64-mer(2), 61-mer, and 59-mer; forthis class, the first compound already used in the clinic
the nucleotide sequences, see Table 1], and ligated with T4 DNAis oxaliplatin [((1R,2R)-diaminocyclohexane)oxalato-
ligase. Full-length substrates were separated from unligated prod-
platinum(II)]. Interestingly, the S,S enantiomer of oxa- ucts in a 6% denaturing polyacrylamide gel, purified by electroelu-
liplatin exhibits a markedly reduced antitumor activity. tion, reannealed, and stored in annealing buffer (50 mM Tris-HCl
[pH 7.9], 100 mM NaCl, 10 mM MgCl2, and 1 mM dithiothreitol)Thus, the stereochemistry of carrier amine ligands of
at 	20
C. Other details of the purification of DNA substrates forcisplatin analogs can modulate their anticancer prop-
NER were the same as described previously [65, 66].erties, but the underlying mechanisms have not been
entirely clarified. The rational design of cisplatin ana-
Proteins
logs containing enantiomeric amine ligands and exhib- Expression and purification of recombinant rat full-length HMGB1
iting improved or alternative antitumor properties re- protein and its domains A (residues 1–84) and B (residues 85–180)
were carried out as described [67, 68]. The residue numbering corre-quires, therefore, an understanding of the molecular
sponds to that in the full-length HMGB1 protein (GenBank, acces-rules governing the effects of enantiomorphism of
sion number Y00463).amine ligands in cisplatin analogs on their biological
efficacy. The pharmacologically relevant target of plat-
Electrophoretic Mobility Shift Assays with HMGB1
inum compounds is DNA. Our present study has clari- Domain Proteins
fied the role of different conformations of the major Radioactively labeled 20 bp probe DNAs (10 nM) were titrated with
HMGB1a or HMGB1b proteins in 10 l sample volumes in buffer I1,2-GG intrastrand crosslinks formed in DNA by two
composed of 10 mM HEPES (pH 7.5), 10 mM MgCl2, 50 mM LiCl,cisplatin analogs containing enantiomeric (2R,3R)-
100 mM NaCl, 1 mM spermidine, 0.2 mg/ml bovine serum albumin,and (2S,3S)-diaminobutane ligands in recognition of
and 0.05% v/v Nonidet P40. For all gel mobility shift experiments,these lesions by DNA binding proteins and repair. The
samples were incubated on ice for 1 hr and made 7% in sucrose
results demonstrate that distinctly different conforma- and 0.017% in xylene cyanol prior to being loaded on running, pre-
tional and other physical properties of these crosslinks cooloed (4
C), prerun (300 V, 1–2 hr) 5% native polyacrylamide gels
(29:1 acrylamide:bisacrylamide, 0.5 TBE buffer (45 mM Tris-HCl,are responsible for their different affinity to HMG-box
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